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IgG4 responses are considered indicative for long-term or repeated exposure to particular antigens. Therefore, studying IgG4-
specific antibody responses against Staphylococcus aureusmight generate new insights into the respective host-pathogen inter-
actions and the microbial virulence factors involved. Using a bead-based flow cytometry assay, we determined total IgG (IgGt),
IgG1, and IgG4 antibody responses to 40 different S. aureus virulence factors in sera from healthy persistent nasal carriers,
healthy persistent noncarriers, and patients with various staphylococcal infections from three distinct countries. IgGt responses
were detected against all tested antigens. These were mostly IgG1 responses. In contrast, IgG4 antibodies were detected to alpha-
toxin, chemotaxis inhibitory protein of S. aureus (CHIPS), exfoliative toxins A and B (ETA and -B), HlgB, IsdA, LukD, -E, -F,
and -S, staphylococcal complement inhibitor (SCIN), staphylococcal enterotoxin C (SEC), staphylococcal superantigen-like pro-
teins 1, 3, 5, and 9 (SSL1, -3, -5, and -9), and toxic shock syndrome toxin 1 (TSST-1) only. Large interpatient variability was ob-
served, and the type of infection or geographical location did not reveal conserved patterns of response. As persistent S. aureus
carriers trended toward IgG4 responses to a larger number of antigens than persistent noncarriers, we also investigated sera
from patients with epidermolysis bullosa (EB), a genetic blistering disease associated with high S. aureus carriage rates. EB pa-
tients responded immunologically to significantly more antigens than noncarriers and trended toward evenmore responses
than carriers. Altogether, we conclude that the IgG4 responses against a restricted panel of staphylococcal antigens consisting
primarily of immunemodulators and particular toxins indicate important roles for these virulence factors in staphylococcal
pathogen-host interactions, such as chronicity of colonization and/or (subclinical) infections.
Staphylococcus aureus is responsible for more deaths annually inthe United States than HIV/AIDS and tuberculosis combined
(1, 2). S. aureus infections can range from mild skin and soft tissue
infections (3) to more severe bacteremia (4) and osteomyelitis (5),
and they can be resolving or chronic. S. aureus is able to persis-
tently adhere to the anterior nares of 30% of all humans, while in
the remaining population this opportunistic pathogen is never or
only incidentally detectable (6–9). It has long been established that
nasal colonization is associated with an increased chance of infec-
tion (10–12). In patients with epidermolysis bullosa (EB), a ge-
netic blistering disease that leaves patients highly susceptible to S.
aureus colonization, nasal carriage rates of 50 to 80% have been
reported, and 75 to 100% of their skin wounds are culture positive
for S. aureus (13–17). Interestingly, although EB patients interact
frequently with S. aureus, bacteremia is seldom reported in these
patients (18).
Numerous S. aureus virulence factors have been identified (19–
24). However, the precise roles of most of these virulence factors
during colonization and pathogenesis in humans have remained
largely unclear, as determination of in vivo expression of bacterial
virulence factors is technically challenging. Burian et al. showed by
a quantitative PCR (qPCR) analysis on samples from 4 persistent
nasal carriers that the adhesin genes clfB, fnbA, and isdA and the
immune modulator gene chp are expressed in vivo (25). In an
artificial inoculation study, clfB proved to be essential for coloni-
zation in humans (26).
Instead of direct in vivo detection of virulence factors, the hu-
man antibody response can be used as an indicator for the in vivo
expression of S. aureus virulence factors (9, 27–29). Our group has
published several reports on human immune responses to S. au-
reus. Persistent carriers have higher IgG titers directed to toxic
shock syndrome toxin 1 (TSST-1) than persistent noncarriers (9).
During bacteremia, patients developed significantly higher IgG
responses than age-matched uninfected controls. These responses
were directed to the immune modulators staphylococcal superan-
tigen-like protein 1 (SSL1), SSL5, and staphylococcal complement
inhibitor (SCIN) and the toxins -hemolysin B (HlgB) and leu-
kocidin F (LukF) (28), indicating that these virulence factors are
produced in vivo during infection. Furthermore, Algerian patients
suffering from various S. aureus infections showed higher IgG
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responses directed to exfoliative toxins A (ETA), ETB, HlgB,
LukD, E, and -S, staphylococcal enterotoxin A (SEA), SEE, SEH,
and SEM than controls (30).
When IgG responses are studied, usually only the total IgG
(IgGt) levels are measured. However, IgGt is composed of 4 dif-
ferent subclasses, each with distinct biological functions and in-
duction patterns (31). IgG1 responses, which represent approxi-
mately 60% of IgGt, are directed primarily against proteins. They
are induced within a week of infection, peak between 1 and 2
weeks, and resolve after 2 to 3 weeks (32). IgG1 functions as a
proinflammatory signal inducing Fc receptor-mediated and com-
plement-mediated phagocytosis. IgG4 antibodies, which repre-
sent approximately 5% of IgGt, are produced after prolonged ex-
posure, typically taking months or years (32, 33). IgG4 antibodies
are reported to not activate or weakly activate complement via the
classical pathway, in contrast to IgG1 antibodies. Furthermore,
IgG4 antibodies are correlated with tolerance after allergy (31, 33,
34), they have a low binding affinity to Fc receptors on phagocytes,
and IgG4-mediated opsonophagocytosis is reportedly less effi-
cient than IgG1-mediated opsonophagocytosis (35).
The aim of our present study was to determine whether anal-
ysis of IgGt, IgG1, and IgG4 directed against virulence factors of S.
aureus could help elucidate the location and duration of exposure
to these bacterial factors during infection. Using a previously de-
veloped bead-based flow cytometry assay (xMap; Luminex) (9,
28), we measured total IgGt, IgG1, and IgG4 antibody responses
directed to 40 different S. aureus virulence factors in sera from
patients suffering from 4 different S. aureus infections originating
from 3 geographical locations. In addition, we studied the hu-
moral responses in sera from healthy carriers, noncarriers, and EB
patients with well-documented S. aureus colonization status, all
from The Netherlands. We looked for infection-specific responses
to the virulence factors of S. aureus and the IgG subclasses in-
volved. Furthermore, we determined IgG subclass/total IgG ratios
to determine the contributions of the different subclasses to the
IgGt response to S. aureus. By studying these responses, we ob-
tained new insights on the (chronicity of) human exposure to S.
aureus and the virulence factors involved, which have implications
for antistaphylococcal vaccine development.
MATERIALS AND METHODS
Sera from healthy volunteers and patients. We included sera from 19
Dutch persistent carriers and 26 Dutch persistent noncarriers (9). An
individual was defined as a persistent nasal carrier when 3 out of 3 nasal
swabs taken 2 weeks apart were positive and as a persistent noncarrier
when all swabs were negative for S. aureus (9). All swabs were processed as
described by Nouwen et al. (36). In addition, we included sera isolated
from 10 Dutch patients with bacteremia at diagnosis and 1, 2, and 3 weeks
after diagnosis (37) and sera from 13 EB patients (18). Furthermore, we
included serum samples from 10 patients without S. aureus-related infec-
tions admitted to the Mustapha Pacha Hospital, Algiers, Algeria, and pa-
tients with either S. aureus skin infections (n 10), joint infections (n
10), or respiratory infections (n 10) 14 days (range, 7 to 34) after strain
identification (30). Serum samples were collected from 60 healthy Suda-
nese volunteers at the University of Khartoum and from 25 Sudanese
citizens with S. aureus skin infections. The Medical Ethics Committee in
the Erasmus Medical Centre approved the study (MEC-2007-106) for
work performed in Rotterdam, The Netherlands. The Medical Ethics
Committee of the University Medical Center Groningen approved the
collection of sera from EB patients (approval no. NL27471,042,09). Local
ethical committees reviewed and approved both Algerian (30) and Suda-
nese (unpublished data) studies. All serum donors provided written in-
formed consent.
Antigens. The antigens used were isolated upon overexpression and
comprised 10 cell wall-associated and 30 secreted S. aureus antigens: al-
pha-toxin (A-Tox); chemotaxis inhibitory protein of S. aureus (CHIPS);
clumping factors A and B (ClfA and ClfB); extracellular fibrinogen-bind-
ing protein (Efb); exfoliative toxins A and B (ETA and -B); fibronectin-
binding proteins A and B (FnbpA and -B); -hemolysin B (HlgB); iron-
responsive surface determinants A and H (IsdA and -H); leukocidin (Luk)
S-PV, LukF-PV, LukD-PV, and LukE-PV; S. aureus surface protein G
(SasG); staphylococcal complement inhibitor (SCIN); serine-aspartate
dipeptide repeat proteins D and E (SdrD and SdrE); staphylococcal en-
terotoxins A to E, G to J, M to O, Q, and R (SEA to SEE, SEG to SEJ, SEM
to SEO, SEQ, and SER); staphylococcal superantigen-like proteins 1, 3, 5,
9, and 11 (SSL1, SSL3, SSL5, SSL9, and SSL11), and toxic shock syndrome
toxin 1 (TSST-1) (30, 38–50) (see Table S1 in the supplemental material).
Besides S. aureus antigens, IgGt (16-16-090707; Athens Research & Tech-
nology, Athens, GA, USA), IgG1 (16-16-090707-1M; Athens Research),
and IgG4 (16-16-090707-4M; Athens Research) were used to assess
whether cross-reactivity existed between subclass-specific detection anti-
bodies. Beads without antigens were used as a negative control.
Measurement of antistaphylococcal antibodies. Serum IgGt anti-
bodies directed against the different S. aureus antigens were simultane-
ously quantified in a multiplex assay using a bead-based flow cytometry
technique (xMap; Luminex Corporation), following previously described
protocols (9, 28, 51). The median fluorescence intensity (MFI) was deter-
mined as the median fluorescence of 100 beads and is used as measure of
immunoglobulins bound to the antigens coupled the beads. IgGt was
detected using goat anti-human IgG–phycoerythrin (PE) from Jackson
Immuno Research (Newmarket, Suffolk, United Kingdom). Subclass-
specific responses were determined using monoclonal mouse anti-human
IgG1 of the IgG1 subclass (05-3300; Zymed, Paisley, United Kingdom) or
monoclonal mouse anti-human IgG4 of the IgG1-k subclass (05-3800;
Invitrogen, Paisley, United Kingdom). All subclass-specific antibodies
were detected using IgG goat anti-mouse–PE (Abcam, Cambridge,
United Kingdom). To assess cross-reactivity between subclass-specific de-
tection antibodies, IgG1 and IgG4 were coupled to microspheres and
incubated with the anti-IgGt, anti-IgG1, or anti-IgG4 detection antibod-
ies. As a positive control, pooled serum from 36 healthy volunteers was
used.
Data analysis. Coefficient of variation (CV) values were determined
by dividing the standard deviation of the measurements by the mean of
the measurements. Values with a CV exceeding 25% were excluded from
further analysis. Control beads without protein coupled were included in
each experiment to determine nonspecific binding. The nonspecific MFI
values were subtracted from the antigen-specific results. Groups were
compared using a Mann-Whitney U test in IBM SPSS Statistics 20. The
Bonferroni correction was applied to P values to correct for multiple test-
ing. The ratios were calculated by dividing the IgG (subclass) signal by the
IgGt signal. The median of these ratios is shown in the figures in the
supplemental material, to determine subclass-specific contributions to
the IgGt signal and to facilitate intergroup comparisons. An increase of
signal in the bacteremic patients was defined as a ratio of1 for all time
points, and this ratio was calculated by dividing the signal at the later time
points by that at the first time point.
RESULTS
Validation of IgG subclass-specific Luminex assay. To compare
S. aureus antigen-specific IgG levels in serum samples, the bead-
based multiplex Luminex assay was applied as described previ-
ously (28, 30, 51, 52), and the level of cross-reactivity between our
detection antibodies for IgG1 and IgG4 and coupled antibodies
was assessed by incubating a bead mixture containing IgGt, IgG1,
and IgG4 with either the anti-IgG1 antibody or the anti-IgG4 an-
tibody. IgG1 antibodies showed 2.7% [(291/10,759) 100] cross-
IgG4 Subclass-Speciﬁc Response to Staphylococcus aureus
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reactivity to IgG4-coupled antibodies. IgG4 antibodies gave 0.4%
[(65/16,096) 100] cross-reactivity to the coupled IgG1 antibod-
ies. Thus, less than 5% cross-reactivity of the detection antibodies
was observed. The CV values ranged between 5% and 37%, and on
average, 20% of all measurements had to be excluded for exceed-
ing the CV value cutoff of 25%, comparable to results from pre-
vious studies (9, 28, 51–55). High CVs were measured mainly for
low MFI signals in the IgG4 Luminex assays (MFI of1000). In all
determinations done here, human pooled serum gave median
MFI values of 2,883 (range, 49 to 15,655) for IgGt, 794 (range, 6 to
16,700) for IgG1, and 73 (range, 0 to 9,379) for IgG4. Taking the
results together, we conclude that our Luminex assay is suitable to
determine both total and subclass-specific responses against S.
aureus antigens.
IgGt, IgG1, and IgG4 antistaphylococcal antibodies in anAl-
gerian discovery cohort. To expand our previous IgGt data (30),
the IgGt, IgG1, and IgG4 responses directed against 40 S. aureus
antigens were determined in a discovery cohort of Algerian pa-
tients with either S. aureus joint (10 patients), respiratory (10 pa-
tients), or skin (10 patients) infections and in 10 Algerian control
patients. Significant differences in IgGt, IgG1, and IgG4 between
groups are shown in Table S2A in the supplemental material.
Ratios of IgG subclass to total IgG were calculated to determine
the contributions of the different subclasses to the IgGt response
to 40 different S. aureus antigens. IgG1, which constitutes approx-
imately 60% of IgGt (31, 32), showed responses directed to almost
all tested S. aureus antigens, similar to results obtained for IgGt
(Fig. 1A). Strikingly, in all groups we observed IgG4 responses
against a restricted panel of antigens, consisting of alpha-toxin,
CHIPS, ETA and -B, HlgB, IsdA, LukD, -E, -F, and -S, SCIN, SEC,
SSL1, -3, -5, and -9, and TSST-1 (Fig. 1B), with only few individ-
uals showing high responses against alpha-toxin, ETB, IsdA, SEC,
and SLL3 and -5 (Fig. 1A and B). These S. aureus virulence factors
are almost all secreted immune modulators. No defined patterns
of IgG1 or IgG4 responses were observed for the different types of
S. aureus infection. Skewed IgG4/IgGt ratios for SER and SSL11 in
joint infections and for SEB in respiratory infections were caused
by single patients with high responses. The interquartile ranges of
all ratios are given in Fig. S1A and B in the supplemental material.
Antistaphylococcal IgGt, IgG1, and IgG4 antibodies in an ex-
panded cohort of Sudanese patients with S. aureus skin infec-
tions and healthy controls. To study the antibody responses in
skin infections in a larger cohort from a different geographical
setting, we measured the relative IgGt, IgG1, and IgG4 levels in
sera of 25 Sudanese patients with S. aureus skin infections and 60
healthy Sudanese volunteers. For this purpose, the same antigens
were used as in the above-described analysis of the Algerian serum
sets (except SasG and SEB). Significant differences in the IgGt,
IgG1, and IgG4 levels between groups are shown in Table S2B in
the supplemental material. IgG1 responses against all tested anti-
gens were detected in sera from both patients and healthy con-
trols, similar to the case for the Algerian discovery cohort (Fig.
2A). Intriguingly, also for the Sudanese serum sets, IgG4 antibody
responses were detected against alpha-toxin, CHIPS, ETA, ETB,
HlgB, IsdA, LukD, -E, -F, and -S, SCIN, SEC, SSL1, -3, -5, -9, and
-11, and TSST-1 (Fig. 2B). Interquartile ranges of all ratios are
given in Fig. S2A and B in the supplemental material. Altogether,
the sera from Algerian and Sudanese patients and the respective
control sera revealed IgG4 responses to a similar subset of the
tested antigens.
Induction of IgGt, IgG1, and IgG4 antistaphylococcal anti-
bodies during progression of bacteremia. As previous reports
have shown that antistaphylococcal IgGt responses reach peak
values after a median of 21 days after diagnosis of bacteremia
(range, 5 to 50) (28, 37), we studied the contributions of IgG1 and
IgG4 to the increase of IgGt. We determined the IgGt, IgG1, and
IgG4 levels in response to 40 S. aureus antigens in serum samples
taken at the acute phase, and 1, 2, and 3 weeks after diagnosis of
bacteremia in 10 Dutch patients. For the last time point, 3 samples
were not available. Antigens against which increased responses
could be determined were counted. Indeed, the IgGt level was
increased during the 3-week observation period with bacteremic
patients, specifically showing increased responses to 6 to 23 anti-
gens (median, 16.5) (see Table S3A and B in the supplemental
material). Patients showed increased IgG1 responses during the
3-week observation period to 1 to 21 antigens (median, 11.5) (Ta-
ble S3A and B). IgG1/IgGt ratios were calculated for antigens
showing an increase in IgGt, IgG1, and IgG4 signals (Fig. 3A).
Notably, the IgG1/IgGt ratios did not vary over time, showing that
an increase in IgGt was caused mainly by an increase in IgG1. The
IgG4 responses were poorly conserved between patients, and also
in these serum sets, these responses were detectable in only a re-
stricted panel of antigens, namely, alpha-toxin, CHIPS, ETA and
-B, HlgB, IsdA, LukD, LukE, LukF, LukS, SCIN, SEC, SSL1, -3, -5,
and -9, and TSST-1 (Fig. 3B). During a period of 3 weeks after the
onset of bacteremia, patients showed increased IgG4 responses to
0 to 13 antigens (median, 6.5) (see Table S3A and B in the supple-
mental material). IgG4/IgGt ratios were calculated for antigens
showing an increase in IgGt, IgG1, and IgG4 signals. This showed
that the IgG4/IgGt ratios did not change over time. Thus, the IgG4
signals increased together with IgGt signals. Interquartile ranges
of all ratios are given in Fig. S3A and B in the supplemental mate-
rial.
Antistaphylococcal IgGt, IgG1, and IgG4 antibodies in a co-
hort of Dutch volunteers with long-term S. aureus exposure. To
determine whether carriers and noncarriers differed in their im-
mune responses against S. aureus, sera were collected from 19
persistent nasal carriers and 26 persistent nasal noncarriers. Sig-
nificantly higher IgGt levels directed to TSST-1 were measured for
carriers than for noncarriers. Significantly higher IgG1 levels di-
rected to TSST-1 were measured for carriers than for noncarriers.
Finally, carriers showed significantly higher IgG4 levels directed to
TSST-1 than noncarriers (see Table S3C in the supplemental ma-
terial). Also, the numbers of antigens to which responses were
detectable were determined. Noncarriers showed IgGt and IgG1
responses to similar numbers of antigens as carriers but trended
toward fewer IgG4 responses (mean, 2.68; range, 0 to 11) than
carriers (mean, 2.95; range, 0 to 12) (Fig. 4). Based on these find-
ings, we studied sera of EB patients to determine whether long-
term exposure to different S. aureus types influenced the numbers
of antigens to which IgG4 responses are elicited. Previous studies
had shown that up to six different types of S. aureus could be
cultured from individual patients with EB (16–18). IgGt showed
levels similar to those in a previous study (18). EB patients differed
significantly from noncarriers in IgGt responses to ClfA and in
IgG4 responses SCIN. EB patients differed significantly from car-
riers in IgGt responses to ClfA and IgG4 responses to SCIN.
Notably, while IgG4 responses to the same restricted panel of
antigens were observed in EB patients as for the other groups
described above, the EB patients showed IgG4 responses to signif-
Swierstra et al.
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FIG 1 IgG1/IgGt and IgG4/IgGt ratios in sera from 40 Algerian volunteers. (A) Median of the IgG1/IgGt ratios in sera from 10 Algerian patients with either joint
(dark gray bars), respiratory (light gray bars), or skin (white bars) S. aureus infections and in sera from 10 Algerian control patients without S. aureus infection
(black bars). On the x axis, the 40 tested S. aureus antigens are listed. The y axis shows the median IgG1/IgGt signal ratios for each particular antigen. Dotted lines
mark 60% (the reported IgG1/IgGt ratio), 30% (50% of this reported value), and 90% (150% of this reported value). (B) Same as for panel A, but showing the
IgG4/IgGt ratios. The dotted line marks 5%, which is the reported IgG4/IgGt ratio.
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icantly more antigens than noncarriers (mean of 5.38 and range of
1 to 11 versus mean of 2.68 and range of 0 to 11; P 0.0013), and
they showed a trend toward responding to more antigens than S.
aureus carriers (mean of 5.38 and range of 1 to 11 versus mean of
2.68 and range of 0 to 12;P 0.1275) (Fig. 4). This implies that the
intense exposure of EB patients to different S. aureus types results
in increased numbers of staphylococcal antigens to which IgG4
responses will develop.
DISCUSSION
In the present study, we investigated the IgG subclass-specific re-
sponses directed against 40 different S. aureus virulence factors.
These responses were measured in the sera from patients from 3
geographical locations suffering from 4 different types of S. aureus
infections. In addition, we studied the humoral response in sera
from healthy human carriers, noncarriers, and patients suffering
from epidermolysis bullosa, with well-documented S. aureus col-
onization status, to gain more insights into the bacterial factors
involved in pathogen-host interaction. Total IgG responses were
detected against almost all antigens in our panel, in agreement
with our previous analyses (9, 28, 30, 37). IgGt responses consisted
mostly of IgG1 responses, consistent with the previously reported
finding that IgG1 composes 60% of IgGt (31, 32). In contrast, in all
serum sets analyzed here we observed that IgG4 antibodies, which
represent approximately 5% of the IgGt response, were detected
to a core panel of S. aureus antigens consisting almost exclusively
of secreted immune modulators, irrespective of the type of hu-
man-pathogen interaction.
IgG4 responses were observed against alpha-toxin, CHIPS,
ETA and -B, HlgB, IsdA, LukD, -E, -F, and -S, SCIN, SEC, SSL1,
-3, -5, and -9, and TSST-1. These immune modulators interact
with both the human innate and acquired immune systems on
many levels. Innate responses affected are chemotaxis, which is
modulated by CHIPS (56), extravasation, modulated by SSL3 and
SSL5 (57), complement activity, which is modulated by SCIN
(58), and Toll-like receptor 2 (TLR2) signaling, which is affected
by SSL3 (59). SEC and TSST-1 modulate adaptive responses by
non-antigen-directed binding of major histocompatibility com-
plex (MHC) class II with T cell receptors, resulting in polyclonal T
cell activation (60). Neutrophils are targeted by the -hemolysin
family (HlgB and LukD, -E, -F, and -S) (20), desmosomes are
targeted by exfoliative toxins (ETA and -B) (61), and alpha-toxin
lyses mononuclear immune cells and platelets (62). SSL9 binds to
monocytes and dendritic cells and blocks the complement system
(63, 64), and no clear function has thus far been described for
SSL1. Interestingly, patterns of IgG4 response varied extensively
between volunteers, indicating that each person is exposed to dif-
ferent virulence factors and/or reacts differently. The different ex-
posure to virulence factors could be explained by the fact that
various genetic backgrounds of S. aureus contain different sets of
virulence factors, and variation may also be due to differences in
regulators or gene expression in various strains (24, 29, 65–69).
IgG4 responses were found to be directed against more differ-
ent antigens in EB patients than in healthy noncarriers. EB pa-
tients are highly susceptible to blistering upon minor trauma due
to mutations in structural proteins of the epidermis and the epi-
dermal-dermal junction. Most likely as a consequence of their
fragile skin, 62% to 75% of these patients are nasal S. aureus car-
riers. EB patients with chronic wounds show higher carriage rates
than patients without chronic wounds (16, 18). Importantly, S.
aureus wound colonization was detected in 92% of the EB patients
with chronic wounds and 69% of the patients without chronic
wounds (13, 16). Serial sampling of three wounds, the left and
right anterior nares, and the throat revealed that 58.3% of the EB
patients with chronic wounds and 43.5% of the EB patients with-
out chronic wounds carried alternating S. aureus types over a pe-
riod of2 years, and during this period, the same S. aureus type
was encountered in only 42.5% of all sampled patients (16–18,
70). This suggests that these patients were exposed to diverse
staphylococcal virulence factors over a prolonged period of time.
Accordingly, our present IgG4 data indicate that repeated expo-
sure to S. aureus in EB patients has led to IgG4 responses directed
against more different staphylococcal antigens, although we can-
not exclude that other forms of (previous) exposure might result
in the development of IgG4. Intriguingly, our IgG4 data indicate a
chronic and repeated exposure for all humans to S. aureus and that
repeated exposure as in EB patients leads to higher levels of IgG4
responses directed against more antigens than is the case in
healthy volunteers. Not all staphylococcal isolates produce all of
the virulence factors tested in the present study, and it therefore
seems likely that some of them have a higher potential to elicit an
IgG4 response than others. Importantly, the presence of IgG4 lev-
els against S. aureus antigens in human individuals may be an
indication of past (chronic) or repeated exposure, possibly in the
form of asymptomatic, self-limiting infections or colonization
(32, 33).
IgG4 is important in neutralizing antibody responses during
tolerance after allergy (34, 71), vaccine development (72), and
immune therapy (73). The increased interest in IgG4 is caused
predominantly by the fact that IgG4 antibodies activate the im-
mune system to a lesser degree by Fc receptor-mediated and com-
plement-mediated phagocytosis than other IgG subclasses, mak-
ing IgG4 ideal for passive immunization therapies. Our finding
that EB patients have the widest spectrum of IgG4 responses while
being fairly resistant to bacteremia may provide interesting clues
for further vaccination research: possibly new vaccination strate-
gies should induce neutralizing IgG4 antibodies by repeated ex-
posure, although a protective role of other adaptive immune re-
sponses cannot be excluded.
The findings we report here were generated in several cohorts,
each from distinct geographical locations. As with many clinical
studies, acquiring sufficient samples and finding appropriately
matched controls are challenging, laborious, and time-consum-
ing. Therefore, we performed an explorative analysis with descrip-
tive statistics based on study cohorts that were relatively small.
Accordingly, no power analysis could be done prior to measure-
FIG 2 IgG1/IgGt and IgG4/IgGt ratios in sera from 25 Sudanese patients with S. aureus skin infection and 60 healthy Sudanese volunteers. (A) Median of the
IgG1/IgGt ratios in sera of 25 Sudanese patients with S. aureus skin infection (white bars) and 60 Sudanese volunteers (black bars). On the x axis, the 38 tested
S. aureus antigens are listed (note that SasG and SEB were not included in this particular analysis). The y axis shows the median of the IgG1/IgGt signal ratios for
each particular antigen. Dotted lines mark 60% (the reported IgG1/IgGt ratio), 30% (50% of this reported value), and 90% (150% of this reported value). (B)
Same as for panel A, but showing the IgG4/IgGt ratios. The dotted line marks 5%, the reported IgG4/IgGt ratio.
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FIG 3 IgG1/IgGt and IgG4/IgGt ratios in sera from 10 Dutch bacteremic patients during disease progression. (A) Median of the IgG1/IgGt ratios in 10 Dutch
bacteremic patients during disease progression. White bars, IgG1/IgGt ratio at diagnosis. Light gray bars, IgG1/IgGt ratio at 1 week after diagnosis. Dark gray bars,
IgG1/IgGt ratio at 2 weeks after diagnosis. Black bars, IgG1/IgGt ratio at 3 weeks after diagnosis. On the x axis, the 17 antigens with increases in either the IgGt,
IgG1, or IgG4 signal are depicted. The y axis shows the median of the IgG1/IgGt signal ratios for each particular antigen. The dotted lines mark 60% (the
reported IgG1/IgGt ratio), 30% (50% of this reported value), and 90% (150% of this reported value). (B) Same as for panel A, but showing the IgG4/IgGt
ratios. The dotted line at 5% marks the reported IgG4/IgGt ratio.
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ment. In this respect, it has to be noted also that previous reports
have shown large interpatient variability (9, 19, 28, 30, 37). Nev-
ertheless, we still observed the restricted panel of antigenic im-
mune modulators to which IgG4 responses were mounted in all
cohorts analyzed. This observation that IgG4 responses are
mounted to a restricted panel of secreted immune modulators of
S. aureus is novel and therefore of value to report. Differences
between noncarriers and carriers with respect to the number of
antigens responded to, as shown in Fig. 4, reach significance with-
out correction (P 0.05) but do not remain significant after the
Bonferroni correction (P  0.0167). We observe a clear trend in
the number of antigens showing IgG4 responses and exposure to
S. aureus, but larger longitudinal follow-up studies based on
power analyses and initial results will be needed to further sub-
stantiate these findings.
To the best of our knowledge, this is the first report on IgG4
responses directed to S. aureus antigens. As we found little cross-
reactivity between the different subclass-specific detection anti-
bodies, we conclude that our Luminex assay is robust and has
potential for application with other clinically relevant pathogens.
Lastly, our study demonstrates a remarkable variation in the com-
position of the human subclass-specific antibody responses to var-
ious antigens of S. aureus, predominantly secreted immune mod-
ulators. This has been consistently observed since the start of
measuring such antibodies and is fully in line with the outcomes of
our previously published analyses (9, 19, 28, 30, 37). Our present
data suggest that there is widespread (asymptomatic) exposure to
S. aureus in the community, and this applies to all groups studied
here, from infected patients to persistent nasal noncarriers. We
therefore hypothesize that interactions between humans and S.
aureus occur extensively and repeatedly and are even more diverse
than currently appreciated. This might have major implications
for research on the respective host-pathogen responses in vivo and
for the development of immunotherapeutic strategies such as ac-
tive and passive vaccination.
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